Market Summary
USD8.34+0.62
Market Closed8.03%
BHC Alerts
BHC Stock Price
BHC RSI Chart
BHC Valuation
BHC Price/Sales (Trailing)
BHC Profitability
BHC Fundamentals
BHC Revenue
BHC Earnings
Price Action
52 Week Range
5.5710.23
(Low)(High)
Last 7 days
-9.9%
Last 30 days
-7.5%
Last 90 days
4.8%
Trailing 12 Months
4.5%
BHC Financial Health
BHC Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for BHC
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-06 | Carson Seana | sold | -55,351 | 8.28 | -6,685 | evp, general counsel |
2023-09-05 | Barresi John S | sold (taxes) | -33,249 | 8.35 | -3,982 | svp, controller & cao |
2023-09-05 | Vadaketh Tom George | sold (taxes) | -366,966 | 8.35 | -43,948 | evp, chief financial officer |
2023-09-05 | Carson Seana | sold (taxes) | -428,664 | 8.35 | -51,337 | evp, general counsel |
2023-09-01 | APPIO THOMAS | sold (taxes) | -119,379 | 8.46 | -14,111 | chief executive officer |
2023-06-30 | Paulson John | acquired | 62,496 | 8.00 | 7,812 | - |
2023-06-30 | ICAHN BRETT | acquired | 33,120 | 8.00 | 4,140 | - |
2023-06-30 | ROBERTSON RUSSEL C | acquired | 31,248 | 8.00 | 3,906 | - |
2023-06-30 | WECHSLER AMY B | acquired | 6,872 | 8.00 | 859 | - |
2023-06-20 | Barresi John S | sold (taxes) | -14,274 | 7.4 | -1,929 | svp, controller & cao |
Which funds bought or sold BHC recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-07 | ACADEMY CAPITAL MANAGEMENT INC/TX | reduced | -57.97 | -560,872 | 398,128 | 0.08% |
2023-08-24 | Alberta Investment Management Corp | reduced | -23.93 | -793,779 | 2,421,600 | 0.02% |
2023-08-23 | WOLVERINE TRADING, LLC | added | 55.79 | 149,484 | 405,484 | -% |
2023-08-23 | Stonebridge Capital Advisors LLC | reduced | -13.89 | -4,360 | 24,800 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -10.37 | -29,303 | 255,554 | -% |
2023-08-16 | GTS SECURITIES LLC | new | - | 930,872 | 930,872 | 0.03% |
2023-08-15 | Rokos Capital Management LLP | new | - | 14,078,100 | 14,078,100 | 0.14% |
2023-08-15 | IHT Wealth Management, LLC | reduced | -10.06 | -10,316 | 82,000 | -% |
2023-08-15 | LAZARD ASSET MANAGEMENT LLC | new | - | 49,000 | 49,000 | -% |
2023-08-15 | GOLDMAN SACHS GROUP INC | added | 18.9 | 2,085,930 | 14,049,700 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
BHC Alerts
Schedule 13G FIlings of Bausch Health Companies
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | nomura holdings inc | 3.6% | 13,030,352 | SC 13G/A | |
| Feb 13, 2023 | goldentree asset management lp | 5.4% | 19,421,054 | SC 13G | |
| May 13, 2022 | va partners i, llc | 4.0% | 14,430,901 | SC 13D/A | |
| Feb 14, 2022 | nomura holdings inc | 5.4% | 19,515,079 | SC 13G | |
| Dec 13, 2021 | glenview capital management, llc | 4.75% | 17,078,657 | SC 13D/A | |
| Jun 21, 2021 | va partners i, llc | 5.0% | 17,941,603 | SC 13D/A | |
| Apr 23, 2021 | meruelo alex | 5.51% | 19,604,777 | SC 13G | |
| Mar 16, 2021 | icahn carl c | 3.98% | 14,169,189 | SC 13D/A | |
| Mar 11, 2021 | icahn carl c | 3.98% | 14,169,189 | SC 13D/A | |
| Feb 24, 2021 | icahn carl c | - | 0 | SC 13D/A |
Recent SEC filings of Bausch Health Companies
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 18, 2023 | 8-K | Current Report | |
| Sep 14, 2023 | 8-K | Current Report | |
| Sep 11, 2023 | 8-K | Current Report | |
| Sep 06, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 8-K | Current Report | |
| Sep 05, 2023 | 4 | Insider Trading | |
| Aug 03, 2023 | 8-K | Current Report |
Peers (Alternatives to Bausch Health Companies)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
LLY | 517.3B | 29.5B | 5.22% | 88.98% | 79.61 | 17.53 | 1.53% | 14.16% |
JNJ | 421.5B | 97.8B | -5.97% | -1.12% | 32.29 | 4.31 | 2.29% | -28.92% |
MRK | 272.8B | 58.3B | -1.68% | 25.60% | 17.88 | 4.63 | 2.00% | -81.24% |
PFE | 191.9B | 77.9B | -7.28% | -24.56% | 8.94 | 2.46 | -23.04% | -26.74% |
BMY | 150.1B | 45.2B | -5.53% | -15.83% | 23.72 | 3.25 | -4.15% | 20.34% |
| MID-CAP | ||||||||
RETA | 6.5B | - | 1.68% | 536.50% | -74 | 4.1K | -86.94% | 71.24% |
PRGO | 4.5B | 4.6B | -12.08% | -16.86% | -67.03 | 0.98 | 6.60% | 42.04% |
| SMALL-CAP | ||||||||
TLRY | 1.9B | 627.1M | -7.75% | -1.79% | -1.34 | 3.1 | -0.20% | -204.67% |
SUPN | 1.5B | 634.0M | -8.17% | -19.68% | 35.6 | 2.43 | 0.62% | -24.59% |
CRON | 842.2M | 109.5M | 18.82% | -27.78% | -5.87 | 7.69 | -2.66% | -32.13% |
INVA | 814.0M | 244.3M | -8.50% | 0.08% | 4.13 | 3.33 | -39.50% | -4.99% |
CGC | 567.0M | 453.3M | 123.19% | -68.11% | -0.46 | 1.25 | -16.04% | 55.90% |
ACRS | 523.7M | 31.2M | 3.50% | -46.76% | -4.97 | 16.8 | 407.54% | -26.47% |
OCUL | 269.4M | 54.6M | -19.05% | -43.62% | -2.97 | 4.93 | 9.39% | -179.16% |
ENDP | - | 2.2B | - | - | - | - | -22.39% | 63.59% |
Bausch Health Companies News
Returns for BHC
Cumulative Returns on BHC
-22.9%
10-Year Cumulative Returns
-16.1%
7-Year Cumulative Returns
-20.9%
5-Year Cumulative Returns
-23.4%
3-Year Cumulative Returns
Risks for BHC
What is the probability of a big loss on BHC?
97.3%
Probability that Bausch Health Companies stock will be more than 20% underwater in next one year
72.7%
Probability that Bausch Health Companies stock will be more than 30% underwater in next one year.
46.9%
Probability that Bausch Health Companies stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does BHC drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Bausch Health Companies was unfortunately bought at previous high price.
Drawdowns
Financials for Bausch Health Companies
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 2.5% | 8,350,000,000 | 8,150,000,000 | 8,124,000,000 | 8,127,000,000 | 8,192,000,000 | 8,325,000,000 | 8,434,000,000 | 8,451,000,000 | 8,478,000,000 | 8,042,000,000 | 8,027,000,000 | 8,038,000,000 | 8,109,000,000 | 8,597,000,000 | 8,601,000,000 | 8,498,000,000 | 8,425,000,000 | 8,401,000,000 | 8,380,000,000 | 8,422,000,000 | 8,505,000,000 |
| S&GA Expenses | 1.3% | 2,763,000,000 | 2,728,000,000 | 2,625,000,000 | 2,639,000,000 | 2,631,000,000 | 2,640,000,000 | 2,624,000,000 | 2,580,000,000 | 2,499,000,000 | 2,340,000,000 | 2,367,000,000 | 2,399,000,000 | 2,475,000,000 | 2,600,000,000 | 2,554,000,000 | 2,512,000,000 | 2,478,000,000 | 2,469,000,000 | 2,473,000,000 | 2,486,000,000 | 2,495,000,000 |
| EBITDA | -100.0% | - | 2,587,000,000 | 2,729,000,000 | 3,146,000,000 | 2,936,000,000 | 2,406,000,000 | 1,954,000,000 | 1,640,000,000 | 1,576,000,000 | 1,906,000,000 | 2,425,000,000 | 1,425,000,000 | 1,400,000,000 | 1,733,000,000 | 1,850,000,000 | - | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.32 | 0.34 | 0.39 | 0.36 | 0.29 | 0.23 | 0.19 | 0.19 | 0.24 | 0.30 | 0.18 | 0.17 | 0.20 | 0.22 | - | - | - | - | - | - |
| Interest Expenses | -6.5% | 1,318,000,000 | 1,409,000,000 | 1,464,000,000 | 1,500,000,000 | 1,466,000,000 | 1,420,000,000 | 1,426,000,000 | 1,462,000,000 | 1,485,000,000 | 1,506,000,000 | 1,534,000,000 | 1,546,000,000 | 1,578,000,000 | 1,602,000,000 | 1,612,000,000 | 1,628,000,000 | 1,630,000,000 | 1,624,000,000 | 1,685,000,000 | - | - |
| Earnings Before Taxes | 113.7% | 25,000,000 | -183,000,000 | -129,000,000 | 249,000,000 | 26,000,000 | -515,000,000 | -1,024,000,000 | -1,439,000,000 | -1,580,000,000 | -1,347,000,000 | -934,000,000 | -2,010,000,000 | -2,151,000,000 | -1,893,000,000 | -1,837,000,000 | -793,000,000 | -1,027,000,000 | -1,582,000,000 | -4,154,000,000 | -4,532,000,000 | -4,632,000,000 |
| EBT Margin | 100.0% | - | -0.02 | -0.02 | 0.03 | 0.00 | -0.06 | -0.12 | -0.17 | -0.19 | -0.17 | -0.12 | -0.25 | -0.27 | -0.22 | -0.21 | - | - | - | - | - | - |
| Net Income | 47.9% | -186,000,000 | -357,000,000 | -225,000,000 | 254,000,000 | 43,000,000 | -407,000,000 | -948,000,000 | -1,170,000,000 | -1,287,000,000 | -1,018,000,000 | -560,000,000 | -1,923,000,000 | -2,043,000,000 | -1,888,000,000 | -1,788,000,000 | -616,000,000 | -917,000,000 | -1,619,000,000 | -4,148,000,000 | -3,291,000,000 | -1,640,000,000 |
| Net Income Margin | 100.0% | - | -0.04 | -0.03 | 0.03 | 0.01 | -0.05 | -0.11 | -0.14 | -0.15 | -0.13 | -0.07 | -0.24 | -0.25 | -0.22 | -0.21 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -730,000,000 | -946,000,000 | -1,409,000,000 | 409,000,000 | 671,000,000 | 1,157,000,000 | 1,525,000,000 | 1,199,000,000 | 997,000,000 | 809,000,000 | 651,000,000 | 908,000,000 | 1,054,000,000 | 1,231,000,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 0.2% | 25,503 | 25,445 | 25,686 | 26,298 | 28,171 | 29,090 | 29,202 | 29,252 | 30,042 | 30,197 | 31,199 | 31,562 | 31,396 | 32,630 | 33,863 | 31,667 | 32,354 | 32,551 | 32,492 | 33,777 | 34,448 |
| Current Assets | 5.3% | 4,461 | 4,237 | 4,247 | 4,010 | 5,417 | 5,836 | 5,607 | 5,324 | 5,450 | 5,392 | 5,342 | 5,671 | 5,278 | 5,504 | 6,969 | 4,305 | 4,467 | 4,275 | 4,211 | 4,742 | 4,639 |
| Cash Equivalents | 11.8% | 579 | 518 | 564 | 486 | 659 | 1,249 | 2,119 | 690 | 642 | 679 | 605 | 977 | 896 | 912 | 3,244 | 825 | 878 | 782 | 721 | 973 | 838 |
| Inventory | 1.5% | 1,240 | 1,222 | 1,090 | 1,056 | 1,073 | 1,045 | 993 | 1,058 | 1,086 | 1,076 | 1,094 | 1,224 | 1,226 | 1,124 | 1,107 | 1,100 | 1,060 | 1,012 | 934 | 971 | 993 |
| Net PPE | 0.2% | 1,599 | 1,596 | 1,600 | 1,507 | 1,545 | 1,579 | 1,598 | 1,584 | 1,590 | 1,556 | 1,567 | 1,550 | 1,496 | 1,450 | 1,466 | 1,390 | 1,372 | 1,341 | 1,353 | 1,341 | 1,355 |
| Goodwill | 0.4% | 11,628 | 11,579 | 11,547 | 12,044 | 12,266 | 12,427 | 12,457 | 12,477 | 12,527 | 12,485 | 13,044 | 13,160 | 13,084 | 13,034 | 13,126 | 13,052 | 13,160 | 13,121 | 13,142 | 13,290 | 13,283 |
| Liabilities | -0.3% | 25,232 | 25,300 | 25,426 | 25,865 | 27,918 | 29,231 | 29,236 | 29,387 | 30,653 | 30,321 | 30,594 | 30,907 | 30,850 | 31,075 | 32,727 | 29,107 | 29,666 | 29,772 | 29,677 | 30,540 | 30,890 |
| Current Liabilities | 1.1% | 3,967 | 3,923 | 3,941 | 3,831 | 4,997 | 4,774 | 5,198 | 5,437 | 5,517 | 4,898 | 4,913 | 4,732 | 4,718 | 4,886 | 6,248 | 3,735 | 3,705 | 3,941 | 3,836 | 4,162 | 4,074 |
| LT Debt, Current | -0.4% | 444 | 446 | 432 | 411 | 150 | - | - | - | - | - | - | - | 1.00 | 4.00 | 1,234 | 100 | 56.00 | 257 | 228 | 298 | 230 |
| LT Debt, Non Current | -0.5% | 20,108 | 20,207 | 20,334 | 20,804 | 21,664 | 23,168 | 22,654 | 22,358 | 23,439 | 23,738 | 23,925 | 24,343 | 24,357 | 24,424 | 24,661 | 23,466 | 24,023 | 23,924 | 24,077 | 24,433 | 24,858 |
| Shareholder's Equity | 86.9% | 271 | 145 | 260 | - | 253 | -141 | -34.00 | - | - | - | 605 | 655 | 546 | 790 | 1,136 | 2,560 | 2,688 | 2,779 | 2,815 | 3,237 | 3,558 |
| Retained Earnings | 0.3% | -9,361 | -9,387 | -9,186 | -8,776 | -9,175 | -9,030 | -8,961 | -9,030 | -9,218 | -8,623 | -8,013 | -7,860 | -7,931 | -7,605 | -7,452 | -5,936 | -5,887 | -5,716 | -5,664 | -5,320 | -4,970 |
| Additional Paid-In Capital | 9.9% | 188 | 171 | 159 | 129 | 104 | 415 | 462 | 437 | 413 | 393 | 454 | 435 | 411 | 396 | 429 | 406 | 384 | 374 | 413 | 409 | 391 |
| Shares Outstanding | 0.1% | 364 | 364 | 362 | 362 | 362 | 361 | 359 | 360 | 359 | 357 | 355 | 356 | 355 | 353 | 353 | 352 | 352 | 351 | 351 | 352 | 351 |
| Minority Interest | -1.2% | 934 | 945 | 952 | 958 | 946 | 75.00 | 72.00 | 69.00 | 76.00 | 73.00 | 70.00 | 68.00 | 72.00 | 71.00 | 73.00 | 78.00 | 87.00 | 86.00 | 82.00 | 84.00 | 91.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 16.2% | -428 | -511 | -728 | -1,179 | 648 | 920 | 1,426 | 1,796 | 1,488 | 1,293 | 1,111 | 951 | 1,210 | 1,349 | 1,501 | 1,586 | 1,593 | 1,476 | 1,501 | 1,760 | 1,728 |
| Share Based Compensation | 5.2% | 142 | 135 | 126 | 124 | 124 | 129 | 128 | 119 | 113 | 109 | 105 | 106 | 105 | 105 | 102 | 99.00 | 95.00 | 90.00 | 87.00 | 82.00 | 79.00 |
| Cashflow From Investing | 8.6% | -297 | -325 | -303 | -247 | 394 | 409 | 409 | 405 | -253 | -277 | -261 | -262 | -265 | -256 | -419 | -396 | -318 | -351 | -196 | -44.00 | 820 |
| Cashflow From Financing | 47.0% | -574 | -1,084 | -474 | 77.00 | -1,044 | -802 | -1,513 | -2,291 | -1,251 | -1,016 | -2,294 | 464 | 107 | 72.00 | 1,443 | -1,314 | -1,226 | -1,215 | -1,353 | -2,693 | -3,737 |
BHC Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenues | ||||
| Revenues | $ 2,167 | $ 1,967 | $ 4,111 | $ 3,885 |
| Expenses | ||||
| Selling, general and administrative | 711 | 676 | 1,436 | 1,298 |
| Research and development | 156 | 127 | 299 | 254 |
| Amortization of intangible assets | 269 | 302 | 542 | 612 |
| Goodwill impairments | 0 | 83 | 0 | 83 |
| Asset impairments | 37 | 6 | 50 | 14 |
| Restructuring, integration, separation and IPO costs | 16 | 35 | 26 | 48 |
| Other (income) expense, net | (83) | 0 | (60) | 2 |
| Total expenses | 1,755 | 1,806 | 3,524 | 3,439 |
| Operating income | 412 | 161 | 587 | 446 |
| Interest income | 7 | 3 | 13 | 5 |
| Interest expense | (319) | (410) | (626) | (772) |
| Gain on extinguishment of debt | 0 | 113 | 0 | 113 |
| Foreign exchange and other | (21) | 4 | (31) | (3) |
| Income (loss) before income taxes | 79 | (129) | (57) | (211) |
| (Provision for) benefit from income taxes | (52) | (10) | (125) | 6 |
| Net income (loss) | 27 | (139) | (182) | (205) |
| Net (income) loss attributable to noncontrolling interest | (1) | (6) | 7 | (9) |
| Net income (loss) attributable to Bausch Health Companies Inc. | $ 26 | $ (145) | $ (175) | $ (214) |
| Earnings (loss) per share attributable to Bausch Health Companies Inc. | ||||
| Basic (in usd per share) | $ 0.07 | $ (0.40) | $ (0.48) | $ (0.59) |
| Diluted (in usd per share) | $ 0.07 | $ (0.40) | $ (0.48) | $ (0.59) |
| Weighted-average common shares | ||||
| Basic (in shares) | 364.8 | 362.2 | 364.1 | 361.5 |
| Diluted (in shares) | 367.1 | 362.2 | 364.1 | 361.5 |
| Product sales | ||||
| Revenues | ||||
| Revenues | $ 2,146 | $ 1,944 | $ 4,068 | $ 3,835 |
| Expenses | ||||
| Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues | 640 | 568 | 1,212 | 1,104 |
| Other revenues | ||||
| Revenues | ||||
| Revenues | 21 | 23 | 43 | 50 |
| Expenses | ||||
| Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues | $ 9 | $ 9 | $ 19 | $ 24 |
BHC Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 579 | $ 564 |
| Restricted cash | 9 | 27 |
| Trade receivables, net | 1,743 | 1,790 |
| Inventories, net | 1,240 | 1,090 |
| Prepaid expenses and other current assets | 890 | 776 |
| Total current assets | 4,461 | 4,247 |
| Property, plant and equipment, net | 1,599 | 1,600 |
| Intangible assets, net | 5,299 | 5,800 |
| Goodwill | 11,628 | 11,547 |
| Deferred tax assets, net | 2,191 | 2,166 |
| Other non-current assets | 325 | 326 |
| Total assets | 25,503 | 25,686 |
| Current liabilities: | ||
| Accounts payable | 515 | 521 |
| Accrued and other current liabilities | 3,008 | 2,988 |
| Current portion of long-term debt | 444 | 432 |
| Total current liabilities | 3,967 | 3,941 |
| Acquisition-related contingent consideration | 197 | 208 |
| Non-current portion of long-term debt | 20,108 | 20,334 |
| Deferred tax liabilities, net | 215 | 202 |
| Other non-current liabilities | 745 | 741 |
| Total liabilities | 25,232 | 25,426 |
| Commitments and contingencies (Note 17) | ||
| Equity | ||
| Common shares, no par value, unlimited shares authorized, 364,063,514 and 361,898,846 issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 10,412 | 10,391 |
| Additional paid-in capital | 188 | 159 |
| Accumulated deficit | (9,361) | (9,186) |
| Accumulated other comprehensive loss | (1,902) | (2,056) |
| Total Bausch Health Companies Inc. shareholders’ deficit | (663) | (692) |
| Noncontrolling interest | 934 | 952 |
| Total equity | 271 | 260 |
| Total liabilities and equity | $ 25,503 | $ 25,686 |
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.